I have the pleasure and privilege to dive into #BPDCN under the amazing mentorship of the one and only Andy Lane Dana-Farber News. 🌞=>TET2=>Skin involvement| RAS=> Systemic involvement | Overt BM (>5%)=>⬇️OS.

Thanks Anand Patel! Was a fun and educational experience putting this together with mentors Dr. Garcia and Dr. Ho 🩸

The impact of molecular ontogeny in AML treated with HMA+VEN is unknown. We found that Secondary ontogeny is selectively responsive to VEN added to HMA and the addition of VEN has no clinical benefit in TP53-mutated AML. rdcu.be/dCCZI Leukemia Journal #amlsm Dana-Farber News

Update: Cigna Healthcare after a peer to peer review Cigna Healthcare denied my request. It was denied by a family medicine practitioner who has never in their life treated a patient with leukemia. In what world are we living here? Cigna Healthcare is this how you treat your patients? Really? Do better!!

What is the optimal therapy in molecularly defined secondary AML?
Our multicenter study tries to answer this important question. Pulisehd today in Leukemia. rdcu.be/dy7hW
Thanks to all collaborators and my good friend and mentor Maximilian Stahl

#AMLsm

1/6 Excited to share our new preprint, out today on #biorxiv , a large #singlecell effort studying response to adoptive cellular therapy for relapsed myeloid malignancy after #HSCT !!

Diagnosis and classification of myelodysplastic syndromes
loom.ly/pqtwDkM #myeloidneoplasia #reviewarticles #reviewseries

A study led by Shai Shimony, MD, Dana-Farber revealed the significant impact of molecular ontogeny classification on outcomes among newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents (HMA) +/- venetoclax (VEN). #ASH23
➡️ ms.spr.ly/6018ippme

This entire session was fascinating. Many thought provoking studies on the nuances of measurable residual disease assessments in myeloid malignancies. Agree with Jacqueline Cook: “understanding underlying biology necessary to interpret clinical findings [and I’ll add MRD]!

Congrats to the next wave of Dana-Farber / Mass General Cancer Center fellows!! An incredible group coming from MGH IM Residents! Matt Meizlish Dylan Martini Ben Ouyang 👨‍🔬👨‍⚕️ Sienna Durbin

We are pleased to share that Bruce Levy, MD, has been named chair of the Department of Medicine. Dr. Levy has dedicated the last 30 years of his career to the Brigham and possesses a tremendous understanding and appreciation of our culture, community and mission.

We are elated to share our very first published medical education research study showcasing how effective The Fellow On Call is as a supplemental resource for trainees in hematology/oncology! 🤩

Check it out here: rdcu.be/dqOw5

#MedEd #HemeOnc #FOAMed

The Brigham and Women's Hospital and Dana-Farber have had a wonderful, collaborative working relationship for 3 decades.

Here's how most of us who work here felt when we heard it was ending.

Really, really sad -- for both us and (especially) for our patients. nejm.org/doi/full/10.10…

🎯 Reduced intensity #HematopoieticCellTransplantation improves overall survival in MDS patients w/ TP53 mutations irrespective of TP53 allelic status #MyelodysplasticSyndrome ➡️ brnw.ch/21wDbev #mpnsm #HCT Coleman Lindsley

Excited to share our paper in Journal of Clinical Oncology: allogeneic HCT should be considered as a curative treatment for all patients with high-risk MDS, even for those with TP53 mutations.
Thanks to all collaborators Coleman Lindsley Corey Cutler Chris Hourigan BMT CTN
ascopubs.org/doi/10.1200/JC…

A new study in Journal of Clinical Oncology by Coleman Lindsley & Dana-Farber researchers suggests that allogenic hematopoietic cell transplant should be considered as a viable option for all patients with high-risk MDS, even those with TP53 mutations.
Research Summary ➡️ ms.spr.ly/60119ujKP

Is the effect of obesity on toxicities and Survival in AYAs with ALL differ by age? who influence most - age or BMI? Would like to thank my amazing mentor Marlise R. Luskin MD, MSCE and collaborators for a wonderful opportunity to try and answer these questions.

Couldn't ask for a better crew to start heme-onc fellowship with!

💩@jeanpadillamd sharing why you should consider Brigham and Women's GI for training!

🌆Mass General Brigham & Harvard University community
🥼Provision of skills & time to grow as a clinician & investigator
👥Faculty🟰Kind, supportive, collaborative

ACG
American Gastroenterological Association (AGA)
ABGH

Dr. AC Gomez AC Gomez sharing why to chose Brigham Yen renal for fellowship training!

🥼 #MedPeds  & tailored training plan
👥Faculty🟰 #mentors , colleagues & friends 
🩺Diverse patient pathology
🏥Access to network of resources Mass General Brigham & Harvard University

BWH Nephrology